Rehabilitation Robots - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Rehabilitation robots market size in 2026 is estimated at USD 1.77 billion, growing from 2025 value of USD 1.51 billion with 2031 projections showing USD 3.89 billion, growing at 17.1% CAGR over 2026-2031. This report is Segmented by Type (Exoskeleton Robots, and More), Therapy Area (Upper Limb Rehabilitation, Lower Limb Rehabilitation, and More), Patient Group (Geriatric, Adult, and More), Mobility Level (Stationary Platform, and More), End User (Rehabilitation Centers, and More), Body Region (Upper Extremity, Lower Extremity), and Geography. The Market Forecasts are Provided in Terms of Value (USD).

Global Rehabilitation Robots Market Trends and Insights

Rapid Post-Stroke Adoption of Upper-Limb Exoskeletons in China and South Korea

Government modernisation plans and an aging demographic accelerate procurement of upper-limb robots. Fourier Intelligence’s GR-2 humanoid, equipped with 53 degrees of freedom, highlights Chinese engineering depth. South-Korean researchers’ “Iron Man” robot brings paraplegic gait support, underscoring regional innovation. Clinical data show weekly Fugl-Meyer gains of 1.979 points with robotic therapy versus 1.198 points by conventional means. Closed-loop systems coupling robotics, sensing, and neuronal microfluidics further personalise post-stroke programs.

National Neuro-Rehabilitation Funding Programs in Germany, France and Italy

Germany’s BARMER pact covering 8.5 million lives illustrates Europe’s strategic turn to robotics for cost-efficient therapy. Italian real-world evidence confirms mixed robot-human protocols lower costs without sacrificing outcomes. EU agencies further advocate automation to mitigate caregiver strain and staffing gaps. Coordinated multicentre trials such as STROKEFIT4 aim to standardise evidence-based deployment.

High Up-Front Capex and Maintenance for Multi-DOF Platforms

Personal exoskeletons list between USD 75,000 and USD 100,000, while full-scale clinic units cost more, straining budgets. Beyond purchase, institutions face maintenance, consumables, and specialised training costs that inflate ownership. Investor sentiment remains positive, yet startups confront long R&D cycles and adoption uncertainty. A Veterans Affairs trial showed device use averaging only 86 minutes per week among 161 participants, highlighting utilisation risk. Italian cost analyses underline the need for optimised therapist-to-patient ratios to justify robotic spend.

Other drivers and restraints analyzed in the detailed report include:

• Shift Toward Home-Based Telerehabilitation Robots Under US Medicare Pilot
• Lightweight Actuator Technology Reducing Device Mass Below 10 kg
• Limited Long-Term Clinical Outcome Evidence vs. Conventional Therapy

Segment Analysis

Exoskeleton robots generated 47.35% of 2025 revenue, underscoring their entrenched position in hospital-based therapy. Wearable soft robots, aided by pneumatic and shape-memory innovation, are projected to post 29.6% CAGR to 2031, signalling swift consumer-grade penetration. Therapeutic robots target repetitive upper-limb tasks, while assistive robots widen daily-living support. Hybrid care pathways increasingly combine rigid exoskeletons for acute phases with soft devices for home follow-up. Wandercraft’s AI-enabled Atalante X and Eve exemplify exoskeleton evolution toward hands-free mobility. Simultaneously, pneumatically actuated hand exoskeletons enhance comfort in neuromotor therapies. This dual-track development keeps the rehabilitation robots market dynamic and user-centred.

Second-generation systems integrate adaptive algorithms that tailor assistance to muscle-activation data, reinforcing motor-learning principles. Modular designs such as OpenExo let clinics mix-and-match components, reducing inventory costs while broadening use cases. Collectively, these trends sustain the rehabilitation robots market through differentiated performance tiers that address severe impairment, moderate dysfunction, and daily life augmentation.

Upper-limb applications control around 54.60% of sector turnover, mirroring stroke prevalence where 80% of patients suffer arm deficits. AGREE trials show comparable clinical improvement to standard care despite reduced treatment time, boosting efficiency. Lower-limb devices such as the ANGEL LEGS M20 deliver similar gait gains while adding muscle-strength benefits. Full-body systems that tie brain-computer interfaces to gait platforms emerge as holistic solutions, uplifting neuroplasticity across multiple joints.

Increasingly, clinicians advocate blended regimens: early full-body gait training to avert compensatory habits, followed by fine-motor upper-limb work in subacute stages. These intertwined protocols underpin the rehabilitation robots market and ensure technology investment aligns with patient-centric outcomes.

The geriatric cohort captures 61.40% of the rehabilitation robots market size in 2025 thanks to rising stroke, osteoarthritis, and frailty episodes. Japanese nursing-home studies show robotic lifts and monitors lower staff turnover and reduce restraint usage. Adults remain the largest absolute user base but grow slower as penetration approaches maturity in developed economies. Pediatric adoption lags amid liability concerns; however, smaller-scale prototypes tailored for cerebral palsy illustrate future promise. Geriatric focus will therefore dominate revenue yet also shape device ergonomics, usability, and remote-monitoring features for home care.

Regulators are progressively refining paediatric safety norms, and grant-funded trials in Europe aim to clarify benefit-risk profiles. Over time, verified child-safe designs could unlock a sizable untapped slice of the rehabilitation robots market.

Complete Report Scope:

• By Type
  • Exoskeleton Robots
  • Therapeutic Robots
  • Assistive Robots
  • Wearable Soft Robots
• By Therapy Area
  • Upper Limb Rehabilitation
  • Lower Limb Rehabilitation
  • Full-Body / Gait Training
• By Patient Group
  • Geriatric
  • Adult
  • Pediatric
• By Mobility Level
  • Stationary Platform
  • Mobile / Over-ground
• By End User
  • Rehabilitation Centers
  • Hospitals and Clinics
  • Homecare Settings
  • Specialty Orthopedic and Sports-Medicine Centers
• By Body Region
  • Upper Extremity
  • Lower Extremity
• By Application
  • Neurological Disorders (Stroke, SCI, CP, Parkinson)
  • Orthopedic Injuries and Post-Surgery
  • Sports Injury Rehabilitation
• By Technology
  • Powered (Motorized / Actuated)
  • Passive / Mechanically Assisted
  • AI-Driven Adaptive Control
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Middle East
    • Israel
    • Saudi Arabia
    • United Arab Emirates
    • Turkey
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Rest of Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America represented 39.60% of 2025 revenue, buoyed by Medicare policy shifts and Veterans Affairs programmes that distribute exoskeletons to spinal-cord-injured veterans. Legislative initiatives such as the STAND Act aim to standardise access criteria, yet VA trials reveal average weekly use below 90 minutes, underscoring utilisation hurdles. Home-based pilots and CMS reimbursement continue to channel growth toward community settings.

Asia-Pacific is the fastest-growing territory with a 21.2% CAGR, led by China, South Korea, and Japan. Fourier’s GR-2 humanoid and Korea’s paraplegic gait robot exemplify regional innovation, while Japan’s nursing-home deployments validate labour-saving benefits. Skill-shortage constraints in India and Brazil could moderate adoption, but rental schemes and international aid projects seek to bridge gaps.

Europe harnesses robust public funding; Germany’s 8.5 million-life reimbursement agreement signifies institutional confidence. Multicentre trials across France and Italy work to validate scalable protocols, while EU agencies emphasise occupational safety and training to mitigate deployment risks. Pediatric liability concerns, particularly under CE-mark regulations, temper near-term uptake but are unlikely to derail the long-range outlook of the rehabilitation robots market.

List of Companies Covered in this Report:

• Bionik Laboratories Corporation
• Cyberdyne Inc.
• Ekso Bionics Holdings Inc.
• ReWalk Robotics Ltd.
• Hocoma AG (DIH International Ltd.)
• Kinova Inc.
• Rex Bionics Ltd.
• Fourier Intelligence
• Wandercraft
• ExoAtlet
• Moterum Technologies
• Myomo Inc.
• Rejoint Srl
• Tyromotion GmbH
• Reha Technology AG
• GOGOA Mobility Robots
• Ottobock SE and Co. KGaA
• Stryker Corp. (Mako)
• Panasonic (HOSPI)
• Honda Motor Co. (Walking Assist Device)

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support